Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer

Journal of Urology

Volumn 186, Issue 6, 2011, Pages 2239-2244

  Smith, Matthew R ^a   Malkowicz, S Bruce ^b   Brawer, Michael K ^c   Hancock, Michael L ^c   Morton, Ronald A ^c   Steiner, Mitchell S ^c  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c GTx Inc   (United States)

Author keywords

fractures, bone; prostate; prostatic neoplasms; thromboembolism; toremifene

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; GONADORELIN AGONIST; OSTEOCALCIN; PLACEBO; TOREMIFENE;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; CANCER THERAPY; CONSTIPATION; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMUR NECK; FRAGILITY FRACTURE; HEART INFARCTION; HEMATURIA; HIP; HUMAN; HYPERTENSION; LUMBAR SPINE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PAIN; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; STROKE; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

AGED; ANDROGEN ANTAGONISTS; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SPINAL FRACTURES; TOREMIFENE;

EID: 80755163628     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.07.090     Document Type: Article

References (23)

1. P.J. Saylor, N.L. Keating, and M.R. Smith Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy J Gen Intern Med 24 suppl 2009 S389
2. Clinical Practice Guidelines in Oncology™, Prostate Cancer, V1 2010 National Comprehensive Cancer Network 2009 Fort Washington, Pennsylvania
3. C.J. Hoimes, and W.K. Kelly Redefining hormone resistance in prostate cancer Ther Adv Med Oncol 2 2010 107
4. S. Kumar, M. Shelley, and C. Harrison Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer Cochrane Database Syst Rev 2006 CD006019
5. N. Sharifi, J.L. Gulley, and W.L. Dahut Androgen deprivation therapy for prostate cancer JAMA 294 2005 238
6. H.S. Kim, and S.J. Freedland Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management Curr Opin Support Palliat Care 4 2010 147
7. H. Isbarn, L. Boccon-Gibod, and P.R. Carroll Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks Eur Urol 55 2009 62
8. M.R. Smith Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors Curr Urol Rep 9 2008 197
9. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448
10. A. Falahati-Nini, B.L. Riggs, and E.J. Atkinson Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men J Clin Invest 106 2000 1553
11. C.W. Slemenda, C. Longcope, and L. Zhou Sex steroids and bone mass in older men Positive associations with serum estrogens and negative associations with androgens J Clin Invest 100 1997 1755
12. M.R. Smith Androgen deprivation therapy for prostate cancer: new concepts and concerns Curr Opin Endocrinol Diabetes Obes 14 2007 247
13. V.B. Shahinian, Y.F. Kuo, and J.L. Freeman Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2005 154
14. M.R. Smith, R.A. Morton, and G. Barnette Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer J Urol 184 2010 1316
15. J. Gingrich, P. Aliotta, and R.A. Morton Phase III trial in men on ADT demonstrates a reduction in hot flashes in men on toremifene 80 mg compared to placebo Can Urol Assoc J 3 2009 S165
16. A. Decensi, P. Maisonneuve, and N. Rotmensz Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial Circulation 111 2005 650
17. B. Ettinger, D.M. Black, and B.H. Mitlak Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 1999 637
18. N. Mantel, and W. Haenszel Statistical aspects of the analysis of data from retrospective studies of disease J Natl Cancer Inst 22 1959 719
19. M.R. Smith, B. Egerdie, and N. Hernandez Toriz Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 361 2009 745
20. H. Fisher, R. Kaufman, and R.A. Morton Toremifene 80 mg phase 3 trial in men on ADT demonstrates improvement in gynecomastia compared to placebo Can Urol Assoc J 3 2009 S164
21. S. Noble, and J. Pasi Epidemiology and pathophysiology of cancer-associated thrombosis Br J Cancer 102 suppl 2010 S2
22. J.A. Caprini, J.I. Arcelus, and J.J. Reyna Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease Semin Hematol 38 2001 12
23. R.J. Lee, P.J. Saylor, and M.R. Smith Treatment and prevention of bone complications from prostate cancer Bone 48 2011 88